Objectives: To study the usefulness of the complexed–to–total (C:T) prostate–specific antigen (PSA) ratio in the early detection of prostate cancer in patients with a total PSA value <4.0 ng/ml.Patients and Methods: Total PSA and PSA complexed to α1–antichymotrypsin were measured in plasma from 193 men with benign prostatic hyperplasia (BPH) and 34 with prostate cancer. The diagnosis was confirmed in 28 BPH and 16 prostate cancer patients by biopsy and in 165 BPH and 18 prostate cancer patients by histological study following transurethral prostatectomy or open prostatectomy.Results: The area under the receiver operating characteristic (ROC) curve was significantly greater for the C:T PSA ratio (0.908) than for total PSA (0.692) (p<0.001). Using a cut–off point of 0.83 for the C:T PSA ratio and regardless of the digital rectal examination (DRE) finding, 20 of the 34 prostate cancer patients would have been given a correct diagnosis (59% sensitivity) and in only 8 of the 193 BPH patients would a biopsy have been necessary (96% specificity). With a cut–off of 0.79, the sensitivity increased to 85% with a specificity of 92%. When the analysis was restricted to the 44 patients with abnormal DRE, the area under the ROC curve for the C:T PSA ratio was 0.919, and a cut–off point of 0.78 gave a sensitivity of 87% and a specificity of 93%. Using a cut–off of 0.63, all prostate cancers were detected (100% sensitivity) and 54% of the negative biopsies would have been eliminated. For the 183 patients diagnosed following surgery, a cut–off of 0.82 gave a sensitivity of 72% and a specificity of 94%.Conclusion: Our results show that the C:T PSA ratio significantly improves the clinical utility of the PSA assay for detecting prostate cancer in patients with total PSA <4 ng/ml, increasing the sensitivity without significantly increasing the number of biopsies.

Keywords:
Complexed prostate–specific antigen, Prostate cancer, Benign prostatic hyperplasia, Plasma, Early cancer detection
1.
Stamey TA, Yang N, Hay AR, McNeal JE, Freiha FS, Redwine E: Prostate–specific antigen as a serum marker for adenocarcinoma of the prostate. N Engl J Med 1987;317:909–916.
2.
Lange PH, Ercole CJ, Lightner DJ, Fraley EE, Vessella R: The value of serum prostate–specific antigen determinations before and after radical prostatectomy. J Urol 1989;141:873–879.
3.
Mettlin C, Littrup PJ, Kane RA, Murphy GP, Lee F, Chesley A, Badalament R, Mostofi FK: Relative sensitivity and specificity of serum prostate–specific antigen levels compared with age–referenced PSA, PSA density and PSA change. Cancer 1994;74:1615–1620.
4.
Heeb MJ, España F, Gittes R, Griffin JH: Prostate–specific antigen–α2–macroglobulin complexes in prostate cancer patient sera. Biochem Mol Biol Int 1995;37:917–923.
5.
España F, Sánchez–Cuenca J, Estellés A, Gilabert J, Griffin JH, Heeb MJ: A quantitative immunoassay for complexes of prostate–specific antigen with α2–macroglobulin. Clin Chem 1996;42:545–550.
6.
España F, Gilabert J, Estellés A, Romeu A, Aznar J, Cabo A: Functionally active protein C inhibitor/plasminogen activator inhibitor–3 (PCI/PAI–3) is secreted in seminal vesicles, occurs at high concentrations in human seminal plasma and complexes with prostate–specific antigen. Thromb Res 1991;64:309–320.
7.
Stenman UH, Leinonen J, Alfthan H, Rannikko S, Tuhkanen K, Alfthan O: A complex between prostate–specific antigen and α1–antichymotrypsin is the major form of prostate–specific antigen in serum of patients with prostatic cancer: Assay of the complex improves clinical sensitivity for cancer. Cancer Res 1991;51:222–226.
8.
Christensson A, Björk T, Nilsson O, Dahlén U, Matikainen M, Cockett ATK, Abrahamsson PA, Lilja H: Serum prostate–specific antigen complexed to α1–antichymotrypsin as an indicator of prostate cancer. J Urol 1993;150:100– 105.
9.
España F, Martínez M, Sánchez–Cuenca J, Vera CD, Estellés A, Jiménez–Cruz JF: Prostate–specific antigen and its complexes with α1–antichymotrypsin in the plasma of patients with prostatic disease. Eur Urol 1996;30:512–518.
10.
Woodrum DL, Brawer MK, Partin AW, Catalona WJ, Southwick PC: Interpretation of free prostate–specific antigen clinical research studies for the detection of prostate cancer. J Urol 1998;159:5–12.
11.
Ravery V, Boccongibod L: Free/total prostate–specific antigen ratio. Hope and controversies. Eur Urol 1997;31:385–388.
12.
Vashi AR, Wojno KJ, Henricks W, Englandm BA, Vessella RL, Lange PH, Wright GL, Scellhammer PF, Weigand RA, Olson RM, Dowell BL, Borden KK, Oesterling JE: Determination of the ‘reflex range’ and appropriate cutpoints for percent free prostate–specific antigen in 413 men referred for prostatic evaluation using the AxSYM system. Urology 1997;49:19–22.
13.
Catalona WL, Colberg JW, Smith DS, Ornstein DK, Shayka JJ: Measurement of percent–free PSA improves specificity for lower PSA cut–offs in prostate cancer screening. J Urol 1996; 155(suppl):422A.
14.
España F, Royo M, Martínez M, Enguídanos MJ, Vera CD, Estellés A, Aznar J, Jiménez–Cruz JF, Heeb MJ: Free and complexed prostate–specific antigen in the differentiation of benign prostatic hyperplasia and prostate cancer: Studies in serum and plasma samples. J Urol 1998;160:2081–2088.
15.
Allard WJ, Zhou Z, Yeung KK: Novel immunoassay for the measurement of complexed prostate–specific antigen in serum. Clin Chem 1998;44:1216–1223.
16.
Schoonjans F, Zalata A, Depuydt CE, Comhaire FH: MedCalc: N new computer program for medical statistics. Comput Meth Prog Biomed 1995;48:257–262.
17.
Partin AW, Catalona WJ, Southwick PC, Subong EN, Gasior GH, Chan DW: Analysis of percent free prostate–specific antigen (PSA) for prostate cancer detection: Influence of total PSA, prostate volume, and age. Urology 1996;48(suppl):55.
18.
Stephan C, Lein M, Jung K, Schnorr D, Loening SA: The influence of prostate volume on the ratio of free to total prostate–specific antigen in serum of patients with prostate carcinoma and benign prostate hyperplasia. Cancer 1997;79:104–109.
19.
España F, Martínez M, Royo M, Vera CD, Estellés A, Aznar J, Jiménez–Cruz JF: Reference ranges for the concentrations of total and complexed plasma prostate–specific antigen and their ratio in patients with benign prostate hyperplasia. Eur Urol 1997;32:268–272.
20.
Keetch DW, Catalona WJ, Smith DS: Serial prostatic biopsies in men with persistently elevated serum prostate–specific antigen values. J Urol 1994;151:1571–1574.
2000
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.